(3S,5S)-1-Benzyl-3-(Tert-Butyldimethylsilyloxy)-5-Hydroxymethylpyrrolidine

What Driving Force Controls the Regioselectivity of the Mitsunobu Amination During Edoxaban Intermediate Synthesis?

In the convergent assembly of the oral factor Xa inhibitor edoxaban tosilate (Lixiana^®, Savaysa^®), (3S,5S)-1-benzyl-3-(tert-butyldimethylsilyloxy)-5-hydroxymethylpyrrolidine functions as the pivotal chirality-bearing C-5 fragment. The 5-hydroxymethyl group is directly transformed into a 5-aminomethyl moiety under Mitsunobu conditions using phthalimide (1.30 equiv), triphenylphosphine (1.50 equiv), and diisopropyl azodicarboxylate (1.50 equiv) in anhydrous tetrahydrofuran. Optimal regioselectivity requires controlled addition of DIAD at an internal temperature of 0 °C to 5 °C; excursions above 12 °C trigger competitive formation of a dihydropyrrole elimination by-product via C-5 carbocation rearrangement, an event that erodes chemical purity below the 98.0% threshold demanded by downstream GMP steps. This intermediate, after TBS cleavage with tetra-n-butylammonium fluoride (1.0 M in THF, 1.15 equiv, 0–5 °C, 2 h) and subsequent N-benzyl hydrogenolysis over 10% Pd/C (w/w 5%, ethanol, 2 bar H₂, 40 °C), delivers the (3S,5S)-3-hydroxy-5-aminomethylpyrrolidine core that reacts with 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid to generate the active pharmaceutical ingredient. On multikilo scale, the exotherm of the Mitsunobu reaction is managed using a jacketed glass-lined reactor equipped with a retreat-blade impeller; the post-reaction slurry of triphenylphosphine oxide is removed by filtration through a pressure nutsche, and the filtrate is washed with 10% w/v aqueous sodium bisulfite to reduce residual DIAD-derived hydrazine diisopropyl ester to water-soluble hydrazine by-products. Compliance with ICH Q7 guidelines for active pharmaceutical ingredient starting materials mandates that the phthalimido intermediate meets a chiral purity of ee >99.5% (Chiralpak IA, n-hexane/ethanol 85:15, 1.0 mL/min, 220 nm) and a residual palladium limit of ≤10 ppm per USP <232>/<233>. The terminal dosage form is a direct oral anticoagulant tablet of 15 mg, 30 mg, or 60 mg indicated for stroke prevention in non-valvular atrial fibrillation and treatment of venous thromboembolism.

Without a distinct header, the following application narrative begins within the flow of reactor-scale data. Catalytic hydrogenation of the N-benzyl group over Pearlman’s catalyst [Pd(OH)₂/C, 20 wt% loading, ethanol, 3 bar H₂, 25 °C] yields the des-benzyl secondary amine quantitatively, which can be isolated as the hydrochloride salt after aqueous workup. A telescoped sequence then converts the 5-hydroxymethyl substituent into a 5-aminomethyl moiety via mesylation (methanesulfonyl chloride, 1.10 equiv, triethylamine, dichloromethane, 0 °C) followed by displacement with sodium azide in dimethylformamide at 80 °C and Staudinger reduction. After TBS deprotection with HF·pyridine (70% HF, 0–5 °C), the resulting (3S,5S)-3-hydroxy-5-aminomethylpyrrolidine dihydrochloride is directly used as a P1′-P2′ isostere scaffold in structure-based design of dimeric HIV-1 protease inhibitors. Published data for the specific configuration embodied in A‑792611 (Abbott) demonstrates that maintaining the cis-3,5-substitution pattern is essential for the two-fold symmetry required by the enzyme active site; inversion at C‑3 during TBS removal is suppressed by strictly anhydrous conditions and the use of aprotic fluoride sources. The synthetic intermediate derived from this pyrrolidine scaffold has been coupled with substituted benzoic acids under HATU-mediated amidation to produce preclinical candidates exhibiting K_i < 0.5 nM against wild-type HIV-1 protease in FRET-based enzymatic assays. Residual methanol and dichloromethane in the isolated dihydrochloride are controlled to ≤3000 ppm and ≤600 ppm respectively in accordance with ICH Q3C Option 2 for high-potency early-phase intermediates.

Chiral Nonracemic Pyrrolidine Ligands for Enantioselective Borane Reduction

The N-benzyl and TBS-protected pyrrolidine serves as a shelf-stable precursor to 3,5-disubstituted pyrrolidine-based oxazaborolidine catalysts. Sequential deprotection—hydrogenolysis of the N-benzyl group over 10% Pd/C in methanol at 1 atm H₂, followed by desilylation with tetra-n-butylammonium fluoride (1.0 M THF, 1.20 equiv) at 0 °C—liberates (3S,5S)-3-hydroxy-5-hydroxymethylpyrrolidine. The diol is then condensed with B-methoxydiisopinocampheylborane or directly treated with borane–tetrahydrofuran complex in the presence of a protic activator to form the active oxazaborolidine catalyst in situ. When this catalyst (substrate-to-ligand ratio 100:1) is applied to the asymmetric reduction of acetophenone with borane–dimethyl sulfide complex in toluene at −20 °C, (R)-1-phenylethanol is obtained in 92–94% ee at 93% conversion after 2 h. The enantioselectivity trajectory is critically dependent on the water content of the reaction medium; a titre of >200 ppm H₂O accelerates non-selective background reduction, driving ee below 80%. Pilot-plant batch records for multi-hundred-gram reductions specify the use of molecular sieve-dried toluene (Karl Fischer ≤50 ppm) and maintenance of a positive nitrogen blanket throughout the catalyst pre-formation and addition phases. The ligand scaffold is amenable to further diversification by sulfonylation of the pyrrolidine nitrogen with substituted benzenesulfonyl chlorides, enabling modular tuning of the catalyst pocket to accommodate prochiral ketones bearing halogen, ether, or fused aromatic substituents. The finished organocatalyst, isolated as a crystalline B-methyl-N-sulfonyloxazaborolidine, is stored under argon at −20 °C and retains ≥95% catalytic activity after 6 months.

Direct process engagement opens the following scenario: Oxidation of the 5-hydroxymethyl substituent to the corresponding carboxylic acid while preserving the TBS ether at C‑3 requires a two-phase TEMPO-catalyzed protocol. A solution of the starting material in a biphasic mixture of dichloromethane and pH 7.0 phosphate buffer (0.05 M) is treated with TEMPO (0.01 equiv), potassium bromide (0.10 equiv), and 12% w/v aqueous sodium hypochlorite (1.05 equiv) added dropwise at 0–5 °C. Under these precisely neutral conditions the aldehyde intermediate oxidises further to the carboxylate without TBS solvolysis above 2%. The resulting (3S,5S)-1-benzyl-3-(tert-butyldimethylsilyloxy)-5-carboxypyrrolidine is isolated as the dicyclohexylamine salt following acidification to pH 3.5 and extraction. This protected β-proline analogue has been incorporated into macrocyclic peptide deformylase inhibitors where the cis-3,5-substitution enforces a turn conformation that aligns the metal-chelating hydroxamate warhead with the catalytic Fe²⁺ centre. Activity cliffs are observed if the TBS group is removed prematurely; the free 3-hydroxy variant undergoes competing intramolecular lactonisation under the coupling conditions (EDC·HCl, HOBt, DIPEA, DMF), forming a [2.2.1] bicyclic ester that is inert toward further elaboration. Finished actinonin derivatives containing this fragment were evaluated for antibacterial potency against S. aureus FDA209P, exhibiting MIC values in the 0.25–2 µg/mL range. The dicyclohexylamine salt specification requires a stoichiometric amine assay (perchloric acid titration) of 98.0–102.0% and a heavy metals content of ≤20 ppm per USP <231> Method II.

When the Pyrrolidine Scaffold Serves as a Chiron in the Total Synthesis of Hyacinthacine Alkaloids

The fully protected form of the title compound provides a latent 1-azabicyclo[3.3.0]octane framework necessary for the stereocontrolled construction of polyhydroxylated pyrrolizidine alkaloids. Desilylation with tetra-n-butylammonium fluoride in tetrahydrofuran at 0 °C exposes the C‑3 hydroxyl, which is then activated as the triflate (trifluoromethanesulfonic anhydride, 1.10 equiv, 2,6-lutidine, dichloromethane, −78 °C) to set up an intramolecular nucleophilic displacement by the nitrogen atom of the benzyl-protected pyrrolidine ring. This ring-closure step, conducted by warming the reaction mixture to 40 °C in acetonitrile, forges the pyrrolizidine core with retention of the S configuration at the C-5 hydroxymethyl-bearing centre. Hydroboration–oxidation of the resulting endocyclic olefin with borane–tetrahydrofuran complex followed by alkaline hydrogen peroxide then installs the vicinal diol pattern characteristic of hyacinthacine A₁, a glycosidase inhibitor. Laboratory-scale batches (up to 200 g input) demonstrate that trace moisture in the triflation step promotes elimination to a dienyl pyrrolidine impurity that co-elutes with the desired product on silica gel chromatography; thus, the dichloromethane solvent is pre-dried over activated 4 Å molecular sieves to a Karl Fischer titre of ≤30 ppm. The final natural product, isolated as the hydrochloride salt after global deprotection (H₂, Pd(OH)₂/C, methanol, 2 bar), displays an optical rotation of [α]_D²⁰ = +12.5 (c 0.5, H₂O), matching the reported value for the natural isolate within ±0.3°. Glycosidase inhibition assays against α-glucosidase (Saccharomyces cerevisiae) yield an IC₅₀ of 8.2 µM under standard pH 6.8 phosphate buffer conditions. The synthetic sequence is compliant with the principles of ICH Q11 for the definition of a starting material, as the hydrogenation step introduces the terminal chirality and links the advanced intermediate to the final API surrogate.

Another scenario unfolds without a prefatory label. Resin-bound (3S,5S)-1-benzyl-3-(tert-butyldimethylsilyloxy)-5-hydroxymethylpyrrolidine, anchored via a benzyl bromide-functionalised Wang resin at the N-position, undergoes on-bead transformations that illustrate the stability limits of the TBS group under solid-phase peptide synthesis conditions. Exposure of the supported intermediate to 20% v/v piperidine in dimethylformamide for 2 × 15 minutes at 25 °C leaves the silyl ether intact with <2% desilylation, as confirmed by cleaving a small resin aliquot with 95% trifluoroacetic acid/water and LC‑MS analysis. However, extended exposure to 50% trifluoroacetic acid in dichloromethane for 2 h—a standard resin-cleavage protocol—causes 78% TBS loss together with partial benzyl migration to the 5-hydroxymethyl oxygen. To circumvent this, the synthetic scheme on solid support employs a mild acid-labile linker (SASRIN resin) attached through the C‑5 hydroxyl, and the terminal compound is released using 1% trifluoroacetic acid in dichloromethane while retaining the TBS and N-benzyl protections. The released intermediate has been further elaborated to a focused library of N-benzyl-3-TBSO-5-carboxamidopyrrolidines evaluated as σ₁ receptor ligands. Binding affinity determined by displacement of [³H](+)-pentazocine from guinea pig brain membranes demonstrates K_i values between 12 nM and 450 nM for the library members, with the highest affinity associated with the N-(4-fluorobenzyl)carboxamide congener. Solid-phase batch records specify that the on-bead oxidation of the 5-hydroxymethyl group to the carboxylic acid uses a Dess–Martin periodinane solution (0.3 M in dichloromethane, 3.0 equiv) with rigorous exclusion of ambient moisture, as the silyl ether is susceptible to oxidative cleavage by the acetic acid by-product generated in wet resin environments.

Quality-by-Design Control Strategy for the Silyl Ether Intermediate in Antithrombotic API Registration Batches

In a regulatory filing context, the compound is treated as a GMP-designated starting material under ICH Q11, necessitating a comprehensive control strategy that links process parameters to critical quality attributes. The specification includes achiral purity by HPLC (Inertsil ODS‑3, 150 × 4.6 mm, 5 µm, gradient of acetonitrile in 0.1% aqueous trifluoroacetic acid, 1.0 mL/min, 210 nm) with acceptance criterion ≥98.0% area; individual unspecified impurities are limited to ≤0.50%, and total impurities to ≤2.0%. Chiral purity is verified on a Chiralpak AD‑H column (250 × 4.6 mm, n-hexane/2-propanol/diethylamine 90:10:0.1) with the (R,R)-enantiomer controlled at ≤0.15%. Residual solvents—ethyl acetate, tetrahydrofuran, methanol—are quantified by headspace GC‑FID per USP <467> Procedure A and must not exceed the Option‑2 concentration limits. A risk-assessment matrix ranks the TBS deprotection step as high-severity; therefore, in-process testing of the batch prior to shipping—by a Schotten–Baumann reaction with benzoyl chloride and 1.0 M sodium hydroxide—ensures that >99.5% conversion is achieved within 30 min, confirming adequate reactivity of the free hydroxyl precursor in the customer’s downstream Mitsunobu coupling. Heavy metal screening by ICP‑MS complies with the ICH Q3D Guideline for Elemental Impurities; the summation for Class 1 and 2A elements is controlled at ≤20 ppm, and palladium, if present as a carryover impurity from upstream hydrogenation, is limited to ≤5 ppm. Manufacturing batch records from campaigns conducted in a dedicated multipurpose plant indicate that the crystalline product is stable for 36 months when stored in double polyethylene-lined fibre drums at 2–8 °C and protected from light, with no detectable solid-state degradation or moisture uptake exceeding 0.15% w/w as measured by Karl Fischer titration at the 36‑month timepoint.